Acadia Pharmaceuticals Hires Chief Executive | GenomeWeb

SAN DIEGO, Calif.--Acadia Pharmaceuticals here, a biotech company engaged in development and use of high-throughput screening technologies for drug discovery, announced the appointment of Leonard Bormann to the position of CEO. Bormann left the post of vice-president of business development at Allergan, where he worked for 14 years.

Mark Brann, Acadia's current CEO who will continue in his roles as chief scientific officer and president, said Bormann's appointment is key for Acadia. "As a lead discovery company, we need this kind of comprehensive expertise," he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.